Treatment of tumors with RARα selective retinoid compounds in combination with other anti-tumor agents
AssigneeAllergan Sales, Inc.
InventorsAlissar Nehme, Richard L. Beard, Roshantha A. Chandraratna
Life of this patent
Estimating the term…
Abstract
Compounds which are specific or selective agonists of RARα receptors in preference over RARβ and RARγ receptors, and particularly compounds of the formula where R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt, are useful for treating a malignant disease or condition in a mammal. In treatment of solid tumors the compound exhibit synergistic anti-proliferative effect with human recombinant interferon.
Claims28
A compound of the formula
- wherein R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt of said compound.
A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula
- wherein R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt of said compound.
A method of combination therapy for treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of administering to the mammal
- a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula
- wherein R is a H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt of said compound, and
- co-administering to the mammal another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.
A method of combination therapy for treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of administering to the mammal a pharmaceutical composition comprising a pharmaceutically
- acceptable excipient and a therapeutically effective dose of a compound that is specific or seletive agonist of RARα receptors in preference over RARβ and RARγ receptors, and
- co-administering to the mammal another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.
Dependencies are inferred from the claim text.